AI drug-discovery startup building models for molecular and antibody design
Biotech📍 San Francisco, CAFounded 2024
Current Valuation
$1.3B
as of 2026-Q2
UNICORN
Chai Discovery applies AI to molecular and antibody design for drug discovery. It appears on both Forbes AI 50 2026 and CB Insights AI 100 2026, making it a high-signal private AI biotech gap for the tracker.
Company Profile
CEO
Joshua Meier
Founded
2024
HQ
San Francisco, CA
Employees
Undisclosed
Total Raised
$225M
Growth
Forbes reported valuation increased from ~$150M to ~$1.3B in 15 months
IPO Status
private
Fundraising Status
Growth · 4 mo ago
privateTotal raised $225M
Secondary Market
Implied price / share
$47.97
Last round price / share
$67.66
vs last round
-29.1%
Open interest
5
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
AIBiotechAI Drug DiscoveryForbes AI 50CB Insights AI 100
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.